Related Experiment Video
Updated: Aug 12, 2026
Orthotopic Aortic Transplantation: A Rat Model to Study the Development of Chronic Vasculopathy
Published on: December 4, 2010
Cardiac allograft vasculopathy: current concepts
H O Ventura1, M R Mehra, F W Smart
1Ochsner Medical Institutions, New Orleans, LA 70121.
Insights
Cardiac allograft vasculopathy, a major cause of late death in heart transplant recipients, is a distinct form of atherosclerosis. Early detection and understanding its unique characteristics are crucial for managing this post-transplant complication.
Area of Science:
- Cardiology
- Transplant Medicine
- Immunology
Background:
- Cardiac allograft vasculopathy (CAV) is the primary cause of late mortality in heart transplant recipients, affecting 15-20% of patients.
- CAV is characterized by concentric, diffuse intimal hyperplasia, intact internal elastic lamina, rare calcification, and rapid progression, distinguishing it from traditional atherosclerosis.
Purpose of the Study:
- To summarize the key features, potential causes, diagnostic methods, and treatment outcomes of cardiac allograft vasculopathy.
Main Methods:
- Review of existing literature on cardiac allograft vasculopathy.
- Comparison of diagnostic modalities including intravascular ultrasound, coronary angioscopy, and coronary angiography.
- Evaluation of current therapeutic strategies, primarily retransplantation.
Main Results:
- CAV presents differently from traditional atherosclerosis, involving myointimal proliferation potentially driven by immunologic and non-immunologic endothelial damage.
- Intravascular ultrasound and coronary angioscopy demonstrate higher sensitivity in diagnosing CAV compared to coronary angiography.
- Retransplantation, while the only definitive therapy, offers only moderate success rates.
Conclusions:
- Cardiac allograft vasculopathy is a significant challenge in heart transplantation, necessitating further research into its pathogenesis and improved therapeutic interventions.
- Accurate and sensitive diagnostic tools are essential for timely management of CAV.
- The limited efficacy of current treatments highlights the need for novel approaches to prevent or treat CAV.
Abstract:
The major cause of late death in cardiac transplant recipients is cardiac allograft vasculopathy, also referred to as cardiac transplant atherosclerosis, which occurs in 15% to 20% of transplant recipients. It differs from traditional atherosclerosis in that it is a concentric and diffuse intimal hyperplastic process; the internal elastic lamina remains intact; calcification is rare; and the disease tends to develop rapidly. Although no definitive reason for cardiac allograft vasculopathy has been established, it has been suggested that it may be caused by a combination of immunologic and nonimmunologic damage to endothelial cells that results in myointimal proliferation. Intravascular ultrasound and coronary angioscopy are more sensitive diagnostic measures of cardiac allograft vasculopathy than coronary angiography. Although retransplantation currently seems to be the only definitive therapy for cardiac allograft vasculopathy, it has shown only fair results.
Related Concept Videos
01:25Cardiomyopathy I: Introduction and Classification
01:29Cardiomyopathy V: Interprofessional Care